
- Image via Wikipedia
Reasons to buy Wyeth
- Misery loves company.
Reasons not to buy Wyeth
- Doesn’t come close to solving Pfizer’s near term need for late-stage pipeline drugs
- Major mergers in pharma almost always destroy shareholder value (Pisano, 2007)
- Fails to address lack of internal R&D productivity (i.e., not a “disease modifying” business move but rather, a superficial band-aid).
- Opportunity cost is too high; Pfizer could buy 10 innovative companies for the cost of 1 Wyeth (e.g., Shire, BioMarin, OSI, Allergan, Forest…) or, move into generics.
- Wyeth’s marketed / late-stage pipeline has issues: Protonix and Effexor lose patent protection by 2011, bifeprunox and Pristiq have been plagued by issues / slow uptake and will probably never reach the combined $4B in projected sales.
I would be astonished if this deal materialized.
———-UPDATE———–
Officially astonished.








Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)
January 26, 2009 at 8:41 am
[...] my last post, I gave five reason for Pfizer not to buy Wyeth and said I would be astonished ...